Alex B. Blair
Johns Hopkins University School of Medicine
Internal medicineRadiologySurgeryOncologyRetrospective cohort studyChemotherapyCarcinomaGVAXImmunotherapyNeoadjuvant therapyPancreatectomyDiseaseMEDLINEPancreatic cancerAdenocarcinomaPancreatic ductal adenocarcinomaCancer researchMedicineCohortGastroenterology
78Publications
17H-index
915Citations
Publications 79
Newest
#1Georgios Gemenetzis (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 17
#2Alex B. Blair (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 17
Last. Matthew J. Weiss (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 48
view all 0 authors...
BACKGROUND The introduction of multi-agent chemotherapy and radiation therapy has facilitated potential resection with curative intent in selected locally advanced pancreatic cancer (LAPC) patients with excellent outcomes. Nevertheless, there remains a remarkable lack of consensus on the management of LAPC. We sought to describe the outcomes of patients with LAPC and objectively define the multidisciplinary selection process for operative exploration based on anatomical factors. METHODS Consecut...
Source
#1Alex B. Blair (Johns Hopkins University)H-Index: 17
#2Lingdi Yin (Johns Hopkins University)H-Index: 5
Last. Jin He (Johns Hopkins University)H-Index: 40
view all 13 authors...
OBJECTIVE: The aim of this study was to characterize the patterns and treatment of disease recurrence in patients achieving a pathological complete response (pCR) following neoadjuvant chemoradiation for advanced pancreatic ductal adenocarcinoma (PDAC). SUMMARY OF BACKGROUND DATA: A pCR is an independent predictor for improved survival in PDAC. However, disease recurrence is still observed in these patients. METHODS: Patients with advanced PDAC who were treated with neoadjuvant therapy and had a...
6 CitationsSource
#1Bradley N. Reames (UNMC: University of Nebraska Medical Center)H-Index: 19
#1Bradley N. Reames (UNMC: University of Nebraska Medical Center)H-Index: 2
Last. Jin He (Johns Hopkins University)H-Index: 40
view all 12 authors...
MiniAn international survey of high-volume pancreas cancer surgeons revealed wide variations in management preferences, attitudes regarding contraindications to surgery, and the propensity to offer exploration. When presented with 6 hypothetical clinical vignettes using details from real patients th
18 CitationsSource
#1Alex B. Blair (Johns Hopkins University)H-Index: 17
#2Robert W. KrellH-Index: 17
Last. Bradley N. Reames (UNMC: University of Nebraska Medical Center)H-Index: 3
view all 12 authors...
BACKGROUND AND PURPOSE There is limited high-level evidence to guide locally advanced pancreas cancer (LAPC) management. Recent work shows that surgeons' preferences in LAPC management vary broadly. We sought to examine whether surgeon volume was associated with attitudes regarding LAPC management. METHODS An electronic survey was distributed by email to an international cohort of pancreas surgeons to evaluate practice patterns regarding LAPC management. Clinical vignette-based questions evaluat...
Source
#1Hyeong Seok Kim (New Generation University College)H-Index: 4
#2Wookyeong Song (UPR-RP: UPRRP College of Natural Sciences)
Last. Jin-Young Jang (New Generation University College)H-Index: 54
view all 57 authors...
BACKGROUND Although we previously proposed a nomogram to predict malignancy in intraductal papillary mucinous neoplasms (IPMN) and validated it in an external cohort, its application is challenging without data on tumor markers. Moreover, existing nomograms have not been compared. This study aimed to develop a nomogram based on radiologic findings and to compare its performance with previously proposed American and Korean/Japanese nomograms. METHODS We recruited 3708 patients who underwent surgi...
Source
#1Lei Zheng (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 39
#2Ding Ding (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 51
Last. Daniel A. Laheru (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 24
view all 37 authors...
Purpose: Immunotherapy is currently ineffective for nearly all pancreatic ductal adenocarcinomas (PDAC), largely due to its tumor microenvironment (TME) that lacks antigen-experienced T effector cells (Teff). Vaccine-based immunotherapies are known to activate antigen-specific Teffs in the peripheral blood. To evaluate the effect of vaccine therapy on the PDAC TME, we designed a neoadjuvant and adjuvant clinical trial of an irradiated, GM-CSF-secreting, allogeneic PDAC vaccine (GVAX). Patients a...
4 CitationsSource
#1Neda Amini (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 27
#2Neda Rezaee (WashU: Washington University in St. Louis)H-Index: 2
Last. Christopher L. Wolfgang (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 102
view all 17 authors...
Abstract Background The aim of this study was to determine the incidence of high-grade dysplasia (HGD) or invasive carcinoma in patients with small branch duct intraductal papillary mucinous neoplasms (BD-IPMNs). Methods 923 patients who underwent surgical resection for an IPMN were identified. Sendai-negative patients were identified as those without history of pancreatitis or jaundice, main pancreatic duct size (MPD) Results BD-IPMN was identified in 388 (46.4%) patients and 89 (22.9%) were ca...
1 CitationsSource
#1Stephen Muth (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 7
#2May Tun Saung (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 6
Last. Lei ZhengH-Index: 39
view all 6 authors...
Abstract Pancreatic ductal adenocarcinoma(PDAC) is resistant to the PD-1/PD-L1 blockade therapy. Previously, the combination of PD-1 blockade and vaccine therapy was shown to have a modest antitumor activity in murine models of PDAC. We used a murine syngeneic model of metastatic PDAC to identify, among multiple T cell modulators tested, which therapeutic agents in combination with the GVAX cancer vaccine and an anti-PD-1 antagonist antibody(αPD-1) are able to improve the survival. We found that...
3 CitationsSource
#1Arsen Osipov (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 5
Last. Lei Zheng (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 39
view all 17 authors...
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, due in large part to its resistance to conventionaltherapies, including radiotherapy (RT). Despite RT exerting a modest antitumor response, it has also been shown to promote animmunosuppressive tumor microenvironment. Previous studies demonstrated that focal adhesion kinase inhibitors (FAKi) inclinical development inhibit the infiltration of suppressive myeloid cells and T regulatory (T regs) cells, and subsequently enhan...
Source
#1Ding Ding (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 51
#2Ammar A. Javed (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 23
Last. Daniel A. Laheru (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 24
view all 50 authors...
Recent research on genomic profiling of pancreatic ductal adenocarcinoma (PDAC) has identified many potentially actionable alterations. However, the feasibility of using genomic profiling to guide routine clinical decision making for PDAC patients remains unclear. We retrospectively reviewed PDAC patients between October 2013 and December 2017, who underwent treatment at the Johns Hopkins Hospital and had clinical tumor next-generation sequencing (NGS) through commercial resources. Ninety-two pa...
1 CitationsSource